The UK and US have agreed to a key commercial pact that will guarantee zero levies on UK medicine shipments entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise expenditure on drugs through the National Health Service (NHS). This move secures that import taxes on these crucial products will remain at zero for a timeframe of the next three years.
This development comes after previous warnings to significantly raise duties on patented pharmaceutical products, with increases mentioned as high as double the cost.
"This agreement between the UK reinforces the global environment for cutting-edge drugs and establishes long-overdue balance to transatlantic drug exports," an announcement said.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's largest export categories to the US, which is by far the biggest destination for major UK drugmakers.
Export figures show that in the one-year period leading up to the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that span.
"This deal protects employment, boosts investment and paves the way for the UK to become a global hub for biotech and pharma," a minister commented.
Detailed UK Commitments
The deal includes several notable commitments from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to stay within budget will be capped at 15%. In the past, repayments exceeded twenty percent.
Recent Tensions
This agreement takes place against a ongoing dispute between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by arguments that American customers were paying a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward American operations.
One official stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
